Innate Pharma
IPHA
10 hedge funds and large institutions have $354K invested in Innate Pharma in 2026 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 2 closing their positions.
50% more capital invested
Capital invested by funds: $235K → $354K (+$119K)
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
11% more funds holding
Funds holding: 9 → 10 (+1)
0.01% more ownership
Funds ownership: 0.2% → 0.2% (+0.01%)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SP
SmartHarvest Portfolios
Poulsbo,
Washington
|
+$39.3K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$25K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$20.6K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$831 |
| 5 |
FFA
Farther Finance Advisors
San Francisco,
California
|
+$18 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$54.7K |
| 2 |
Millennium Management
New York
|
-$12.9K |
| 3 |
GI
GAMMA Investing
Foster City,
California
|
-$382 |
| 4 |
RhumbLine Advisers
Boston,
Massachusetts
|
-$25 |
| 5 |
CIAM
Caitong International Asset Management
Hong Kong
|
-$3 |
IPHA Hedge Fund Activity: Q2 2026 in Review
10 of the 8,334 institutional investors tracked by Wall St. Rank reported a position in Innate Pharma (IPHA) for Q2 2026, worth a combined $354K — up 50% from $235K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new IPHA positions and 2 closed out — a net gain of 1 holder — while 2 added to existing stakes and 3 trimmed.
The largest buyer was SmartHarvest Portfolios, opening a new position worth an estimated $39.3K. The largest seller was Jane Street, cutting an estimated $54.7K.
- 10 institutional investors held Innate Pharma (IPHA) as of Q2 2026, up from 9 in Q1 2026.
- Funds reported $354K of Innate Pharma stock for Q2 2026, up 50% quarter-over-quarter.
- 3 funds opened new Innate Pharma positions in Q2 2026 and 2 closed out, a net change of +1 holder.
- The largest Innate Pharma buyer in Q2 2026 was SmartHarvest Portfolios, an estimated $39.3K added.
- The largest Innate Pharma seller in Q2 2026 was Jane Street, an estimated $54.7K sold.
Based on aggregated 13F filings for Q2 2026.